BeOne Medicines Ltd (HK:6160)
:6160
Want to see HK:6160 full AI Analyst Report?
6160 Stock Chart & Stats
HK$193.20
HK$5.50(5.26%)
At close: 4:00 PM EST
HK$193.20
HK$5.50(5.26%)
Day’s Range― - ―
52-Week RangeHK$144.10 - HK$229.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.08M
Market Cap
HK$231.80B
Enterprise ValueHK$27.65B
Total Cash (Recent Filing)HK$4.83B
Total Debt (Recent Filing)HK$2.05B
Price to Earnings (P/E)57.1
Beta0.89
Next Earnings
Aug 21, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding1,426,363,900
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$259.07Price Target Upside34.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)4.09
Revenue Forecast (FY)HK$50.84B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundThe transition to sustained net profitability after prior losses indicates the business has reached a structurally healthier earnings profile. Durable positive net income supports reinvestment in R&D, lowers reliance on external financing and strengthens resilience to cyclical shocks over the next several quarters.
High Gross MarginsExceptionally high gross margins imply strong product economics and pricing power, enabling significant operating leverage as sales scale. This margin structure supports sustainable profitability, improved cash conversion and capacity to fund new trials or commercialization without proportionate cost increases.
Robust Free Cash FlowSubstantial and growing free cash flow provides durable internal funding for development and commercialization, reducing dilution risk. Strong cash generation gives management optionality for targeted R&D, potential partnerships, or debt repayment, enhancing long-term strategic flexibility.
Bears Say
Growth NormalizationA marked slowdown from prior hyper-growth to low single-digit TTM growth suggests the company is moving into a steadier phase. Persistently lower top-line expansion reduces margin-leverage benefits and raises pressure to deliver new product launches or broaden indications to sustain medium-term revenue momentum.
Rising LeverageMaterial increase in absolute debt and leverage reduces financial flexibility and raises interest and refinancing risk. If growth or cash conversion weakens, elevated debt amplifies downside, potentially constraining R&D investment or forcing more costly funding choices over the next several quarters.
Pipeline Setback: Halted KRAS TrialStopping an early KRAS program is a structural hit to pipeline diversification and future revenue optionality. It raises execution risk and increases dependence on remaining assets and trials, meaning fewer long-term growth drivers and greater sensitivity to outcomes of the core programs.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$144.10 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$231.80B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 69 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on May 06, 2026. The company reported HK$1.181 earnings per share for the quarter, beating the consensus estimate of HK$0.879 by HK$0.302.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 1.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,426,363,900 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$1.181 in its last earnings report, beating expectations of HK$0.879. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$259.07 (34.09% Upside)
HK$259.07 (34.09% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
12.04%
Trailing 12-Months
Asset Growth
47.56%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeiGene Ltd. is a global biotechnology enterprise, grounded in scientific research, committed to developing groundbreaking and economical pharmaceutical products. Its core mission is to enhance therapeutic outcomes and broaden patient access to critical medicines across the world. The company was co-founded by Xiao Dong Wang and John V. Oyler on October 28, 2010, and its corporate headquarters are situated in George Town, KY.
6160 Stock 12 Month Forecast
Average Price Target
HK$259.07
▲(34.09% Upside)
Technical Analysis
Innovent Biologics
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Options Prices
Currently, No data available
---